TCR and BCR insights for immuno-oncology
Predict patient response with immune sequencing
Data from examining the immune repertoire of cancer patients can be used to identify patterns associated with positive outcomes and monitor the progress of immunotherapies in clinical trials. Single cell immune sequencing technologies provide an even more granular view of individual T cell or B cell populations following immunotherapy, providing unprecedented detail for informing cancer treatment.
Immune repertoire analysis for diagnosis, prognosis, and treatment monitoring
- Clonal propagation and repertoire diversity correlate with diagnosis/prognosis
- TCR and BCR expression patterns correlate with treatment efficacy
- Novel immune sequencing tools enable tracking of all 7 chains for the entire length of immunotherapy studies
Single cell immune sequencing to track treatment efficacy
- Identify paired receptor sequences for downstream Car-T development or validation purposes
- Characterize progression-free survival following neoantigen treatment
- Track expansion of tumor specific cytotoxic T cells
- Explore the role of TCR diversity in improving clinical outcomes
Applied immune sequencing in the setting of metastatic melanoma
Pre-treatment blood-based factors predict response to neoantigen vaccine + anti-PD-1 combination immunotherapy
Watch this webinar to learn how combining TCR repertoire profiling and immunophenotyping is a strong predictor for response to immunotherapy.
A CASE STUDY IN RENAL CELL CANCER
Patients who respond positively to treatment exhibit distinct immune repertoire signatures.
With immune repertoire sequencing, you can:
- Quantify all seven immune repertoire chains
- Observe changes in the expression levels of the tumor
- Track matched clonotypes over time
- Track CDR3s across FFPE and PBMC samples
- Gauge treatment efficacy with TCR Beta expression level correlations
